Biotech and Pharmaceutical Industry Events & Conferences

Summary

Welcome to the Target Discovery World Congress, combining our successful Screening and Ion Channel Targets conferences into one multi-track event.

This year's event will take place at the South San Francisco Conference Center.

Keynote Speakers
Jeffery Conn
Lee E. Limbird Professor of Pharmacology
Director, Vanderbilt Program in Drug Discovery

Rathnam Chaguturu
Director, High Throughput Screening Laboratories, Courtesy Research Professor-Molecular Biosciences, University of Kansas

Joseph McGivern
Research Director, Lead Discovery,
Amgen

Agenda Topics
   
•    Target Identification and Validation

•    Ion Channel Targets

•    G-Protein Coupled Receptors

•    Protein Kinase Targets

•    Ubiquitin Targets

•    Nuclear Receptor Targets

•    Cell-Based Assays

•    High Content Analysis

•    HTS Platforms

For more information visit: http:///www.selectbiosciences.com/conferences/TDWC2009/

Summary

Welcome to the Microarray World Congress where you will hear about the latest developments and applications in the rapidly expanding field of microarrays.

This year's event will take place at the South San Francisco Conference Center.

The conference will be co-located with the Lab-on-a-Chip World Congress and Molecular Diagnostics World Congress. Registered delegates will also have access to these meetings ensuring a very cost-effective trip.

Make the most of your trip by also attending a pre-conference training course or market tutorial.

Key Note Speaker
Stephen Hewitt
Chief, Tissue Array Research Program, National Cancer Institute, Maryland

Agenda Topics
•    CGH Arrays
•    ChIP-on-ChIP
•    Methylation Detection
•    Protein and Antibody Arrays
•    Lipid Arrays
•    Molecular Diagnostics
•    Emerging Technologies

For more information visit: http://www.selectbiosciences.com/conferences/MWC2009

Summary

Welcome to the Lab-on-a-Chip World Congress, designed to review existing and new life science applications of microfluidic technologies.
This year's event will take place at the South San Francisco Conference Center.

The conference will be co-located with the Microarray World Congress and Molecular Diagnostics World Congress. Registered delegates will also have access to these meetings ensuring a very cost-effective trip.

Make the most of your trip by also attending a pre-conference training course.

Keynote Speakers

Teruo Fujii
Professor, University of Tokyo

James Landers
Professor, University of Virginia

For more information visit: http://www.selectbiosciences.com/conferences/LOACWC2009

Summary

Welcome to the 2nd Molecular Diagnostics World Congress, this year's event will take place at the South San Francisco Conference Center.

The conference will be co-located with the Microarray World Congress and Lab-on-a-Chip World Congress. Registered delegates will also have access to these meetings ensuring a very cost-effective trip.

Register now and save up to $100!

Make the most of your trip by also attending a pre-conference market tutorial.

Keynote Speakers

Samir Hanash - Program Head, Molecular Diagnostics,Fred Hutchinson Cancer Research Center

John Quackenbush - Professor,Harvard School of Public Health

Agenda Topics

•     * Molecular Diagnostics & Biomarkers
•     * PGx and Personalized Medicine
•     * Emerging Technologies
•     * Clinical Applications of Molecular Diagnostics
•     * Commercial & Regulatory Perspectives

Big savings on group bookings!
Click here for more information.

Confirmed Speakers
Edward Abrahams, Executive Director, Personalised Medicine Coallition

Call for Papers
Deadline: 9 February 2009
If you would like to be considered for an oral presentation at this meeting, submit an abstract for review now!

Call for Posters
Deadline: 26 June 2009
You can also present your research on a poster while attending the meeting. Submit an abstract for consideration now!

For more information visit: http://www.selectbiosciences.com/conferences/MDWC2009

Summary

With the success of the inaugural Pharmaceutical Regulatory Affairs Asia in 2008, IBC is hosting the 2nd Pharmaceutical Regulatory Affairs Asia conference in Singapore again this year from 24-25 August 2009.

Last year, we focused on practical strategies in managing regulatory developments specifically in Asia, as well as preparative efforts in the eve of the ASEAN harmonization, on top of other critical regulatory concerns from product approval to post-market product monitoring.

2nd Pharmaceutical Regulatory Affairs Asia serves to further the discussion from last year by turning the limelight on the currently ongoing ASEAN pharmaceutical regulatory harmonization as well as emerging issues along the process of regulatory submission, product registration, approval, post-market surveillance as well as change management.

For more information visit: http://https://www.ibc-asia.com/ibcasia/marlin/system/render.jsp?MarlinViewType=MARKT_EFFORT&site

Summary

Select Biosciences is pleased to announce that we are planning to hold the inaugural Drug Delivery Summit on the 2nd, 3rd and 4th of September 2009, at Dexter House in Central London. This event will be split into three one day symposiums, which will cover all aspects of the current technologies and techniques used in the drug delivery sector.

The subjects to be covered will be:
•    Delivery of Small Molecules & Nucleic Acids
•    Delivery of Macromolecules
•    Formulation & Solubility

Our Keynote Speakers will be:
Esther Chang Professor, Georgetown University Medical Center
Jean Marc Aiache Professor Emeritus, University of Auvergne

For more information visit: http://www.selectbiosciences.com/conferences/DD2009/

Summary

Building on the momentum of last year's record-breaking, sold-out event, the Pharma CI Conference & Exhibition continues to be THE INDUSTRY'S GOLD STANDARD, for senior level pharma, biotech, device, and healthcare professionals seeking the latest news, and the rare chance to network with all the industry's luminaries.
This is best and largest gathering of pharmaceutical competitive intelligence/ business intelligence professionals!   

Please review our website for the 250 list of attendees from 2008 as well as our 2008 program agenda.  ALL the "who's who" of the competitive intelligence community attend annually.   View our website to see their comments about our groundbreaking 2008 conference.  This continues to be the can’t miss, BIG event of the year! 
 
For more information, please visit www.pharmaciconference.com


For more information visit: http://www.pharmaciconference.com/index.html

Summary

Addressing the key challenges for safety professionals Worldwide - Health
Network Communications would like to announce the forthcoming World Drug
Safety Congress that is taking place in London, United Kingdom in September
2009. This conference follows the huge success of World Drug Safety Congress
2007 and 2008, to which Health Network attracted a record number of drug
safety professionals and decision makers to explore the prevalent challenges
of today.

The 3rd annual World Drug Safety Congress Europe brings together top
pharmaceutical, biotechnology and regulatory representatives in a forum that
addresses the key issues of the industry. The in-depth programme covers the
detection, analysis and prevention of adverse drug reactions with case
studies and industry experiences as well as global regulatory coverage of
developments in the US, Japan, Europe, Asia/Pacific, South America and
Canada. The meeting is set to bridge the gap between international
regulatory bodies, industry professionals and academic representatives and
address how to drive pharmacovigilance operations forward into the 21st 
Century

For more information visit: http://www.healthnetworkcommunications.com/2009/safety

Summary

World Pharmaceutical China Summit 2009

For more information visit: http://www.reportbuyer.com/industry_events/results.html?q=china&city=&x=16&y=7

Summary

Welcome to the 6th annual RNAi Europe - Europe's largest conference & exhibition dedicated to RNA interference. This year's event will take place in the exciting city of Berlin.

The conference will be co-located with Advances in qPCR, Peptides Europe, and the Epigenetics World Congress. Registered delegates will also have access to these meetings ensuring a very cost-effective trip.

Register now and save up to €100!

Make the most of your trip by also attending a pre-conference tutorial.

Keynote Speakers

Jens Kurreck
Professor,
University of Stuttgart

Andy Miller
Professor,
Imperial College London

For more information visit: http://www.selectbiosciences.com/conferences/RNAiE2009

Summary

Select Biosciences' inaugural Epigenetics World Congress will be co-located with Advances in qPCR, Peptides Europe and RNAi Europe.  Registered delegates also have access to these meetings, ensuring a cost-effective trip.

 

To make the most of your trip, why not attend one or both of the pre-conference tutorials.  The Course Tutor for both is Enal Razvi, Ph.D.

 

Epigenetics, Pluripotency and Reprogramming Market Analysis and Business Tutorial

13:00 – 15:00, 16 September 2009

 

MicroRNA Diagnostics, Therapeutics and Cancer Personalized Medicine Market Analysis and Business Tutorial

15:30 – 17:30, 16 September 2009

For more information visit: http://www.selectbiosciences.com/conferences/EWC2009/

Summary

Welcome to the inaugural Peptides Europe conference and exhibition. This year's event will be held in the exciting city of Berlin.

The conference will be co-located with RNAi Europe, Advances in qPCR, and the Epigenetics World Congress. Registered delegates will also have access to these meetings ensuring a very cost-effective trip.

Agenda Topics:

*    New Approaches in Peptide/Protein Synthesis
*    Biosynthetic Chemistry
*    Structure-Function Relationship
*    Peptide Biotechnology and Diagnostics
*    Pharmacology and Medical Peptide Chemistry
*    Bioinformatics in Peptide Research

For more information visit: http://www.selectbiosciences.com/conferences/PtE2009/

Summary

Select Biosciences' 2nd annual Advances in qPCR conference will take place in Berlin, and will be co-located with RNAi Europe, Peptides Europe and Epigenetics World Congress. Registered delegates will also have access to these meetings, ensuring a very cost-effective trip.

To make even more of your trip, why not also attend one of the pre-conference training courses:
TATAA Biocenter qPCR Training Course - Biostatistics
09:00 – 17:00, 16th September.

Introduction to qPCR  
09:00 - 17:00, 16th September.

For more information visit: http://www.selectbiosciences.com/conferences/AqPCR2009/index.aspx

Summary

SMi's inaugural Biological Production conference looks to address the main areas of the production of biological products, process scale-up and validation, comparability issues and technology transfer, with a series of case studies from industry leaders. 

Hear methods for the development of an integrated approach to your mammalian cell line development from Pfizer, the utilisation of scale process models in your process scale-up from BTG and the importance of communication in technology transfer from Novartis.

With large pharma, biotechs and CMO's all coming together to discuss the challenges they face in their production of biological products, don't miss an opportunity to learn from their experience at this conference.

Benefits of Attending:

•    OPTIMISE your scale-up of processes with advice from the experts
•    DISCOVER ways to minimise the pitfalls when transferring technology
•    HEAR case studies from Pharma companies and learn from their mistakes

PLUS A FULL DAY POST-CONFERENCE WORKSHOP

A Quality by Design (QbD) Framework for Biopharmaceutical Glycosylation During Production
23rd September 2009, Copthorne Tara Hotel, London, UK
In Association with: Ludger UK

To Register visit: www.smi-online.co.uk/biological5.asp

ACADEMIC AND GROUP DISCOUNTS AVAILABLE!!

For more information visit: http://www.smi-online.co.uk/events/overview.asp?is=4&ref=3150

Summary

The most comprehensive antibody event for science, business, strategy and networking –   Antibodies A-Z

Terrapinn's 5th annual antibody and antibody alternative event hits the .

 

Monoclonal antibodies are the fastest-growing segment within the pharmaceutical industry, achieving a compound annual growth rate of around 14% and driving the value of the biologics markets towards $106 billion by 2010.  Last year, combined global sales totaled more than $20 billion, and there is no indication this pace will slowdown anytime soon. 

 

This is a pivotal time for the future of antibody and antibody alternative development.  Our understanding of monoclonal antibodies and antibody alternatives has grown enormously, resulting in more product launches, greater competition and enhanced potential to treat patients.

 

Key topics

The pharmaceutical industry landscape

Identifying antibody targets

Non-activating antibody formats

Strategies to minimize immunogenicity

De novo selection of high affinity antibodies

Tailoring antibodies to enhance target site distribution

Enhancing effector function

Bi-specific antibodies

Antibody drug conjugate development

Next generation biologics

Regulatory & approval process updates for monoclonal antibodies and biologics Follow on and second generation biologic

 

Who's attending?

 

·         Pharmaceutical companies

·         Biotechnology companies

·         Contract service organizations

·         Government

·         Academic/ research institutions

·         Consultants

·         Venture capitalists

 

 

Your marketing platform to access North America's top pharmaceutical and biotechnology companies

 

Americas Antibody Congress is THE forum for senior-level executives in the biotech & pharmaceutical industries to gather together to discuss this soon-to-be $30 billion industry. By joining as part of this targeted event, you will find out more about how to develop your business and get more involved in this rapidly changing market. This is your opportunity to position yourself as a market-leader and have your company stand out from the crowd.

 

Who should sponsor:

• Assay & technology providers
• CROs
• CMOs
• Lawyers
• Drug device manufacturers
• Consultants
• Labs and lab equipment providers
• Biotechnology companies
• Any service providers to the BioPharm antibody industry.

 

Online www.terrapinn.com/2009/antibodyusa | email michael.weinberg@terrapinn.com | phone +1 212 379 6320 | fax +1 212 379 6319

For more information visit: http://www.terrapinn.com/2009/antibodyusa

Summary

DigiPharm 2009 is one of the largest gatherings of pharmaceutical marketing and communications professionals in Europe. It will discuss the challenges and strategies used to enhance online communication, customer relationship, strengthen brand awareness and improve profitability in digital marketing.

This is your one-stop-shop to the most up to date online marketing strategies, regulatory low down, measuring ROI, analytical tools and more.

Issues to be addressed at the 2009 congress include:

•    Creating the perfect marketing mix for your product
•    How can digital marketing technologies be used to improve online communication with physicians?
•    Specialist e-marketing skills; e-detailing integration, customer relationship management systems  to tailor your marketing campaign
•    Integrating your online and offline marketing
•    The use of search engine marketing to create brand awareness
•    Regulatory landscape review
•    How do you utilise web 2.0 and new media? Blogs, You Tube, Networking sites, Wikipedia
•    Rich media marketing and how best to utilise the following: podcasts, videos, mobile
•    Measuring ROI; what are the tracking and analytical tools available?

Visit the conference website (www.healthnetworkcommunications.com/2009/digipharm) to see the most updated list of speakers, conference programme and to register.

Contact Julie Phillips, Senior Marketing Manager if you have an enquiry on +44 (0) 207 608 7039 or email jphillips@healthnetworkcommunications.com.

For more information visit: http://www.healthnetworkcommunications.com/2009/digipharm

Summary

Day One – Product Authorisations

*       Understand the data requirements for your products:  human health, environmental, efficacy testing and labelling claims

*       Learn from real life experiences of product dossier preparation and submission

*       Hear practical advice for dealing with the commercial implications caused by product authorisation

*       Access the best regulatory advice - Member state feedback on product evaluations

Day Two – Revision of the BPD

*       Hear Commission and industry feedback on the draft proposal and possible implications for industry

*       In depth analysis of key elements of the draft text

*       Take part in interactive discussions with those driving the regulatory reforms

Don't Miss

Don't forget to reserve a place at one of the interactive workshops.  A combination of taught sessions and practical exercises providing key knowledge that can be implemented at your place of work

22 September 2009- Choice of 2 Pre Conference Workshops

1 - Dossier Preparation for the BPD

2 - Understanding the Requirements of CLP

23 September 2009 – Evening Discussion and Dinner

Assessment of Different Options to Address Risks from the Use Phase of Biocides - “COWI Report”

25 September 2009 – Post Conference Seminar

Conducting Risk Assessments under REACH and the BPD

   
Key Presentations

Key regulatory updates from The EU Commission, JRC and 7 Member States

          o Erik van de Plassche, JRC-IHCP
          o A Representative, DG Environment
          o Martina Rauch, Federal Institute for Risk Assessment, Germany
          o Jorgen Larsen, Danish Environmental Protection Agency, Denmark
          o Dr Peter Howden, Health and Safety Executive, UK
          o Edmund Platner, Federal Ministry of Agriculture, Forestry, Environment and Water Management, Austria
          o Annette E. Smits-van Prooije Ph.D., CTGB, Board for the Authorisation of Plant Protection Products and Biocides, The Netherlands
          o Vibeke Bernson, Swedish Chemicals Agency, Sweden

For more information visit: http://www.iir-events.com/IIR-conf/LifeSciences/EventView.aspx?EventID=2348

Summary

With an exceptional line-up of speakers, Biomarkers in Clinical Trials conference will demonstrate the way forward in designing phase I, II and III trials.
 
Attend and gain insights into the use of biomarkers as a way of accelerating the approval or withdrawal of a product. You will have the chance to network with industry associates and the opportunity to explore ways in which you can integrate biomarkers into your own drug development processes.
 
This conference will also be focusing on the following areas:

•    Transfer of biomarkers to clinical practice
•    Biomarkers in early clinical drug development
•    Biomarkers in later stage clinical trials (phase II and III)
•    Examples of successful use of biomarkers in clinical trials
•    Potential for saving money by using biomarkers
•    Biomarkers for disease modification in chronic disease
•    Pre-clinical / clinical modeling
•    Utilising positive and negative effect biomarkers in clinical trials
 
 
Hear keynote addresses from:

•    Stefan Scherer, Global Biomarker Program Leader and Head of Biomarker Angiogenesis, F. Hoffmann-La Roche
•    Alessandra Vitaliti, Head of Cellular Biomarkers Group, Novartis
 
Our expert speaker line-up also includes:

•    Stewart Bates, Director of Biomarker Discovery, GlaxoSmithKline
•    Paul de Koning, Vice President and Head of Exploratory Development, Astellas
•    Birgitte Søgaard, Divisional Director, Clinical Pharmacology and Translational Medicine, H. Lundbeck
•    Fernando Ulloa-Montoya, Biomarkers Leader, Cancer Immunotherapeutics R&D Department, GlaxoSmithKline Biologicals
•    Simon Read, Leader of Biomarkers and Experimental Medicine, Roche Pharmaceuticals
•    Stefan Sultana, Clinician and Translational Medicine Leader, Pfizer
•    Patrick Y. Mueller, Project Leader for Safety Assessment, Novartis Institutes for BioMedical Research
•    Rose McCormack, Clinical Research Scientist, Astrazeneca
•    Mauro D'Antonio, Manager of Biomarker Testing Platforms, Merck Serono
•    Feng Luo, Senior Scientist, Experimental Imaging, Abbott Laboratories
 

Review the full programme at: www.smi-online.co.uk/biomarkers-ct7.asp

To reserve your place at this event visit our website at: www.smi-online.co.uk/biomarkers-ct7.asp

Alternatively call Zain Philbey on tel: +44 (0) 20 7827 6722 or email: zphilbey@smi-online.co.uk


For more information visit: http://www.smi-online.co.uk/events/overview.asp?is=4&ref=3151

Summary

For the 2nd annual meeting, the agenda will reflect the dynamic nature of the field as we move from fundamental stem cell research towards clinical therapies. With a multidisciplinary range of speakers the meeting, co-located with the World Biobanking Summit, truly encompasses “bench to bedside” stem cell research. 
 
The conference will begin with a special business and ethics session on the afternoon of 23 September.
Make the most of your trip by also attending a market analysis/business tutorial or training course:
Market Analysis and Business Tutorials

Stem Cells in Drug Discovery and Regenerative Medicine
09:00 – 12:30, 23 September 2009

Epigenetics, Pluripotency and Reprogramming
17:30 – 19:30, 24 September 2009

Training Course
Stem Cells – Basic Science
09:50 – 17:30, 23 September 2009

For more information visit: http://www.selectbiosciences.com/conferences/SCE2009/

Summary

This interactive conference offers an unrivalled opportunity for you to meet European Regulators and to learn from experiences of the data submitted. With a wide selection of up-to-the-minute case studies from renowned experts from industry and research centres, this meeting will provide practical, problem-solving strategies for implementing the Environmental Risk Assessment which you cannot afford to miss.

*       Ensure that your dossier is accepted first time - understand the new requirements for testing protocols for dung organisms

*       When is it OK not to use radio labelling? Understand which studies will be accepted by the regulators and which studies will not

*       Save money and time - understand the benefits of data sharing

*       Stay one step ahead of the game! Benefit from tips and advice from those that are moulding the legislation in this area

*       Keep up to date with the latest technologies and methodologies to ensure that your ERA protocol is efficient and cost effective

For more information visit: http://www.iir-events.com/IIR-conf/LifeSciences/EventView.aspx?EventID=2366

Summary

Agchem Forum 2009 - 3 Conferences, 1 Exhibition

Stream 1 Human Risk: Toxicology and Exposure
Stream 2 Environmental Risk: Ecotox and Fate
Stream 3: Regulations: directive 91/414/EEDC and MRL Regulation (EC) No 396/2005

Don't Miss

Opening Plenary Discussion : Food Security and the Importance of Crop Protection

Over the next few decades, the global food system will come under renewed pressure from the combined effects of seven fundamental factors: population growth, the nutrition transition, energy, land, water, labour and climate change. The combined effects will create constraints on food supply and if action is not taken, there is a real potential for demand growth to outstrip increases in global food production. Effects on developing countries would be devastating. Developed countries will be affected too. Expectations of abundant and ever cheaper food could come under strain. The EU can no longer afford to take its food supply for granted. Without effective crop protection tools over 40% the crops grown in Europe could be lost at pre or post harvest.  If Europe is to deal effectively with growing food security concerns it has to ensure farmers have access to effective crop protection tools. Is the new Pesticide Authorisation Regulation and its hazard based pesticide cut off measures a step in the wrong direction for the EU?

Speaker Panel:
Professor Witzke, Humbolt, University of Berlin, Germany
Dr Ian Denholm, Rothamsted Research, UK
Robert Sturdy MEP
Christa Klaß, MEP (subject to availability)
Dominic Dyer, Chief Executive, Crop Protection Association, Us
   
Who Will You Meet?

6 EFSA speakers offering expert scientific opinion
Anja Friel,  EFSA, Italy
Luc Mohimont, EFSA, Italy
Dr Manuela Tiramani, EFSA, Italy
Dr Christine Füll, EFSA, Italy
Mark Egsmose, EFSA, Italy
Hermine Reich, EFSA, Italy

Practical advice from MS experts
Dr Bernd Stein, Federal Institute for Risk Assessment BfR, Germany
Dr Martina Erdtmann-Vourliotis, BVL, Germany
Dr Karsten Hohgardt, Federal Office of Consumer Protection and Food Safety (BVL), Germany
Jörn Wogram, Federal Environment Agency (UBA), Germany
Jose Tarazona, INIA, Spain
Thierry Mercier, AFSSA, France
Anne Alix, AFSSA, France
Vibeke Bernson, Swedish Chemicals Authority, Sweden
Jeroen J. Meeussen, Ctgb, The Netherlands

Real Life Company Insight
Syngenta Crop Protection AG, Bayer CropScience, DuPont, IVA

For more information visit: http://www.iir-events.com/IIR-conf/LifeSciences/EventView.aspx?EventID=2351

Summary

Don't Miss

NEW for 2009!

•First insights from ECHA on registrations and feedback on the development of their SIEF IT tool

•Hear the first practical experiences of SIEF operations

•Understand how Member States plan to enforce REACH

•Receive practical advice on managing your responsibilities for identifying a substance in an article

•Learn which substances will be targeted by Member States for Annex IV

•Hear first hand industry experience of an inspection

•Understand classification considerations necessary under REACH

•Inclusive networking drinks reception


   
Who Will You Meet

Meet representatives from ECHA, CEFIC and 5 Competent Authorities at one event!

Anthony Wilson, Head of Unit for Registration, ECHA, Finland

Erwin Annys, REACH Responsible, CEFIC, Belgium

Richard Bishop, HM Inspector of Health and Safety, Health and Safety Executive, UK

Sten-Åke Svensson, Head of Department for Industrial and Consumer Chemicals, Swedish Chemicals Agency (KemI), Sweden

Yvonne Mallooly, Senior Inspector, Environmental Risk Assessment, Health and Safety Authority, Republic of Ireland

Dick Sijm, Head, Bureau REACH, RIVM, The Netherlands

Giuseppe Malinverno, Corporate Government and Regulatory Affairs Manager, Solvay, Belgium

Steve Groome, Global Regulatory Affairs & Product Stewardship Manager, Rhodia, UK

Ali Temara, EMEA Regulatory Affairs Senior Manager, Procter & Gamble, Belgium

Phil Todd, HSE Classification, Syngenta, Switzerland

Barry Podd, Global Regulatory Affairs Manager, Kimberly Clark, UK

James White, FRIC, REACH Programme Director, Dow Corning Corporation, US

Christian André Thonhauser, Director Research and Development, THONHAUSER GmbH, Austria

Francesca Zoete Maglia, Reach Data Specialist, Firmenich SA, Switzerland

Béatrice Decelle, Regulatory Affairs Advisor and REACH Coordinator, Abermarle Europe SPRL, Belgium

Froukje Balk, Consultant Chemicals Management, Royal Haskoning, The Netherlands

Meglena Mihova, Partner, EPPA, Belgium

Ruxandra Cana, Partner, Field Fisher Waterhouse, Belgium

Andrew Fasey, Consultant, Protection Through Knowledge Ltd, UK



For more information visit: http://www.iir-events.com/IIR-conf/LifeSciences/EventView.aspx?EventID=2353

Summary

Welcome to the inaugural World Biobanking Summit and exhibition, which will be held in the beautiful and historic city of Edinburgh.

The conference will be co-located with Stem Cells Europe, and registered delegates will have access to both meetings ensuring a very cost-effective trip.

 

Make the most of your trip by also attending the co-located market analysis/business tutorials:

 

Stem Cells in Drug Discovery and Regenerative Medicine

09:00 – 12:30, 23 September 2009-06-09

 

Epigenetics, Pluripotency and Reprogramming

17:30 – 19:30, 24 September 2009

For more information visit: http://www.selectbiosciences.com/conferences/BE2009/

Summary

2nd Pharma Marketing Asia Summit 2009 will be a key platform for Asian pharmaceutical industry stakeholders, such as you, to discover how we can deal with these challenges while revamping our marketing functions in how it reaches out to a changing group of stakeholders.

At Asia's only dedicated marketing forum for pharma industry practitioners, expect to:

Strategise on doing more while conserving resources under changing pharmaceutical market conditions Assess the impact of health reforms and market access considerations to develop growth opportunities Understand the growing influence of the public healthcare sector in your market share of the future Identify strategies to preserve and increase market share even as generics become more prevalent Examine the relevant tools to improve market performance in different Asian markets Gain invaluable insights from over 20 leading regional practitioners and your industry peers Dedicated networking time of over 10 hours with over 60 decision makers from pharmas, distributors and sector experts

For more information visit: http://https://www.ibc-asia.com/ibcasia/marlin/system/render.jsp?MarlinViewType=MARKT_EFFORT&site

Summary

Select Biosciences' 2nd Advances in BioDetection Technologies will be a one day summit held in the cosmopolitan city of London. It will offer attendees the opportunity to minimize time away from the office and travel costs whilst still providing an excellent overview of the sector and an opportunity to network with its key players.

Our Keynote Speaker will be William Trogler, Professor, University of California San Diego
Agenda Topics are:

• Next Generation Biosensors and Biodetection Techniques
• Point of Care and Field Ready Pathogen Detection Devices 
• Nucleic Acid Diagnostics Tests

For more information visit: http://www.selectbiosciences.com/conferences/BDT2009/

Summary

The Chinese government has recently announced the establishment of the country's biggest siRNA R&D complex in Kunshan (near Shanghai) which will house both basic research and commercial startup companies.

In partnership with local organizers, Select Biosciences has been asked to host this inaugural international conference (circa. 500 expected). Attendance represents a major opportunity to forge brand new links and collaborations as this area will be the centre of RNAi activities in China going forwards.

Agenda Topics
•    Target Discovery and Validation
•    Transfection
•    siRNA Therapeutics
•    in vivo RNAi
•    siRNA Library Screens
•    microRNAs in

o    Disease Biology
o    Stem Cell Biology
o    Diagnostics
o    Virology
o    Biogenesis
o    Development

Make the most of your trip by also attending the post-conference Market Analysis and Business Tutorial:
RNAi Market Analysis and Business Tutorial
13:00 – 17:00, 16 October 2009

For more information visit: http://www.selectbiosciences.com/conferences/RNAiA2009/

Summary

Americas largest phase I strategy congress - Exploratory Clinical
Development World Americas attracts record numbers of early clinical
development scientists and decision makers to explore the challenges of
phase I trials. It addresses the critical issues in achieving seamless
first-in-man studies and also provides advice on how to conduct effective
clinical studies that facilitate making the right decisions early on in
exploratory clinical development.

For more information visit: http://www.healthnetworkcommunications.com/2009/explorusa

Summary

Point of care testing (POCT) promises delivery of rapid diagnosis to speed treatment of patients in a setting that is convenient for both the clinician and the patient, but can it deliver?  This question and many more will be tackled at SMi's 6^th annual Point of Care Diagnostics Conference on 26^th and 27^th October in London.

The conference will examine these challenges and give you the tools you need to tackle them.  With case studies from clinicians, regulatory insight from the FDA and market analysis by top consultants, they will address the following topics:

• Emerging and disruptive technologies
• Clinical needs
• Connectivity and patient pathways
• Health service requirements
• Market trends and dynamics
• Regulatory affairs and compliance
• Reimbursement and funding

PLUS HALF DAY ASSOCIATED POST-CONFERENCE WORKSHOP
How Do We Achieve Concordance Between POCT and Central Lab Tests?
28^th October 2009, Crowne Plaza Hotel - St James, London,

In association with: Nova Biomedical

For more information visit: http://www.smi-online.co.uk/09pointofcare5.asp

Summary

It is essential for pharmaceutical companies to develop a comprehensive P&R strategy and they must adapt their policy over time according to the market environment. A failure to recognise this can reduce a product's value and prevent it from reaching its full potential.  

SMi's 15th Annual European Pharmaceutical Pricing and Reimbursement Conference will bring you the information you need to understand the dynamics of the market and create an effective policy for your own organisation in future pricing scenarios. The programme will feature presentations from industry specialists working at a corporate level, country-specific case studies from EU member states and an exclusive chance to hear the latest insights from representatives of the European Commission itself.

 

 

Why should you attend this event?

 

• Hear about the impact of different European P&R systems on the industry
• Understand the effect of pricing and reimbursement on the internal market
• Learn about the Integration of Market Access during clinical development
• Gain insights into processes and methods used for technology appraisal

 

HALF DAY PRE-CONFERENCE WORKSHOP
Cooperation with Payors as a Means for Attaining Reimbursement

27th October 2009, Marriott Courtyard Munich City Center,
In Association with: Roman Rittweger

For more information visit: http://www.smi-online.co.uk/09europricing4.asp

Summary

The congress is the single most focused event in Europe dedicated to key technological and scientific trends in proteins engineering, expression and production in the Biopharma, pharmaceutical and biotech industry in the UK & Europe.

For more information visit: http://www.proteins-congress.com

Summary

The congress attracts over 100 senior attendees from pharmaceutical, biotechnology and academic institutions in Europe. Topics covered include GPCR’s in Medicinal Chemistry, In Silico, Modulation, Screening, Signalling as well as GPCR Discovery Programmes

For more information visit: http://www.gpcr-congress.com

Summary

Commercial and development opportunities for big pharma, biotech, investors and research organizations


The only stem cell & regenerative medicine event in North America that brings science and business together.

The flood gates opened when President Obama reversed restrictions on embryonic stem cell research.  Now stem cell researchers, biotechs and big pharma companies are in a race to bring the first embryonic stem cell treatment to the market.

The combination of recent regulatory advances and a large number of products nearing late stage clinical trials have set the stage for a new era. Industry leaders now hunger to identify strategies and nourish relationships which will fast track research, development and commercialization of stem cell therapies and applications in the global marketplace.  Stem Cells USA & Regenerative Medicine Congress has been created to satiate this need.

 Stem Cells USA & Regenerative Medicine Congress will explore the scientific and business aspect of this rapidly growing market. Industry experts will cover all the main topics - discovery & development of stem cells, potential applications, regulation and partnering for success. This is where global pharmaceutical companies, biotechs, academics and investors gather todiscuss innovation, market opportunities and partnership models.

Topics to be discussed:

.        Funding and partnership models 

.        Stem cells as tools in predicting drug toxicity 

.        Stems cells as tools in drug discovery - target identification and validation 

.        Effective utilizations of iSP cells 

.        Novel strategies for study of disease 

.        Commercialization challenges 

.        Regulatory updates & strategies to overcome regulatory hurdles 

.        Reimbursement and IP issues

.        Enhanced production and manufacturing systems 

.        Big pharma perspective on future commercialization of stem cell
therapeutics 

.        The challenge of commercialization 

.        Cardiovascular stem cell therapeutics 

.        Skin, bone and hair stem cell therapeutics

For more information visit: http://www.terrapinn.com/2009/stemcellsusa/

Summary

Oxford Global Conferences is proud to present qPCR Congress 2009 which is to be held on the 16th & 17th November 2009 in London. The congress is the single most focused event dedicated to key technological and scientific trends & advances in qPCR in the pharmaceutical and biotech industry.  There is also a post conference workshop on Biostatistics on the 18th November.

For more information visit: http://www.qpcr-congress.com

Summary

The 2nd annual World Generic Medicines Congress Americas 2009 is one of the
largest North American generics strategy events on the calendar - The 2nd
annual World Generic Medicines Congress Americas 2009 addresses the health
economics, pricing and competition pressures facing the generics sector in
US and building scale and value through globalization.

For more information visit: http://www.healthnetworkcommunications.com/2009/genericsusa

Summary

Following on from the success of our Asthma & COPD conference, SMi are pleased to announce our COPD: Novel Therapeutics & Management Strategies conference.  Aiming to redress the imbalance in asthma & COPD drug development this conference offers timely and interesting scientific discussion regarding the future of R&D in this field.  Leading experts in respiratory drug development will come together to discuss the important factors affecting their decisions in this area, along with the therapeutic approaches in their pipelines.

 

Key Benefits of Attending:

 

• HEAR from leading researchers in the COPD field
• DISCUSS novel therapeutics and the hopes for the future
• LEARN about the important differences between Asthma & COPD, causing the need for unique therapies
• DISCOVER the latest developments in inhalation technology for the treatment of COPD
  
  

 

PLUS HALF DAY ASSOCIATED WORKSHOP

Inhalation – Technology and Formulation Challenges into the Future

18^th November 2009, Le Méridien, Munich,

Hosted by Fadi Eskandar, Novartis,

 

This workshop aims to address the challenges of respiratory drug delivery and offer solutions in the form of the latest breakthroughs in formulation and device development.

 

For more information visit: http://www.smi-online.co.uk/2009copd4.asp

Summary

Following on from the success of our inaugural event, the SMi Group are proud to present their 2^nd annual conference on Cell-Based Assays.

 

Through a variety of presentations from our expert speaker panel, this event aims to address a number of key issues within this field of research. Hear a keynote presentation from Clay Scott of AstraZeneca who will discuss label-free screening for GPCR ligands, giving answers to some topical questions. Additionally, Darren Cawkhill of Pfizer will discuss improvements to cell line generation, giving case studies on fluorescence activated cell sorting and automation.

 

From label-free screening to high contents analysis in early drug discovery, this event caters for an assortment of people involved in this challenging area. It is a must-attend event for those looking to broaden their knowledge and meet the key people in the field of Cell-Based Assays.

 

Key benefits of attending:

 

• GAIN an in depth understanding of the developments with label-free technologies
• HEAR expert presentations on the topical issue of 3D cell cultures
• DISCUSS novel technological advances

MEET the leading experts and professionals in the field of cell-based assays

For more information visit: http://www.smi-online.co.uk/09cellbasedassay4.asp

Summary

Late stage drug development is growing at around 20% annually, exceeding the
growth rate of Phase II and III Trials. In excess of $12 billion is
currently being spent on Phase IIIb/IV studies as public concerns on the
safety of approved drugs prevail together with the need to evaluate real
world safety and effectiveness of marketed drugs. More than ever before
there is the urgent need to detect, quantify and communicate patient risk
with speed and efficiency.

As a result, Health Network Communications is delighted to announce the
first ever strategic forum addressing the major challenges in conducting
strategic and compliant late stage studies.

For more information visit: http://www.healthnetworkcommunications.com/2009/LSDD

Summary

SMi are proud to present their 4th annual Cold Chain Distribution Conference, the only based cold chain event. Following the success of previous events, this year's conference will highlight the recent regulatory changes in the area as well as hearing from industry leaders working in the field.

The dangers associated with temperature sensitive products going out of range are well documented and serious - this conference will help you to avoid these unnecessary costs.

The conference will be covering a wide range of topics, including:

·                  Managing costs in the face of rising energy prices 

·                  Enhancing packaging 

·                  Temperature logging 

·                  Environmental sustainability 

·                  Risk assessments for efficiency

·                  Ambient temperature storage and transport

Ambient temperature storage and transport The dangers associated with temperature - sensitive products going out of range are well documented and serious - this conference will help you to avoid these unnecessary costs.

For more information visit: http://www.smi-online.co.uk/09coldchain4.asp

Summary

How will drug manufacturing respond to the current global recession?

The current economic crisis affects everyone, however the drug manufacturing industry can continue to thrive through cost of goods reduction, increasing productivity and promoting efficiency.
World Drug Manufacturing 2009 is the only conference and networking event this year to give you the strategies to continue to be successful through the challenging times ahead.
Current issues to be addressed include:

•  Optimising processes to reduce costs
•  Satisfying regulatory cGMP and quality guidelines
•  Creating a lean and proficient supply chain
•  Tackling the global threat of drug counterfeiting
•  Implementing new organisational structures to promote efficiency

For more information or to view the full programme visit the event website: www.wdmsummit.com or call us on +44 (0) 207 202 7573

For more information visit: http://www.wdmsummit.com

Summary

The first annual Health Technology Assessment World Europe, held in
association with the London School of Economics was the most influential
meeting on HTA for pharmaceutical products in 2008. Over the course of the 3
days over 100 participants from the world's leading pharmaceutical and
biotechnology product manufacturers plus government agencies, academic
institutions, contract service organisations and consultancies attended
Health Technology Assessment World.

This is the 2nd annual policy forum for the industry where all the major HTA
agencies across the world and leading pharmaceutical pharmaceutical
companies discuss the challenges in obtaining market access. 

For more information visit: http://www.healthnetworkcommunications.com/2009/hta

Summary

This unique international conference provides a platform for all pharmaceutical scientists, internists and primary care physicians to discuss and learn about all the important international breakthrough developments on drug discovery and on new therapeutics.

A conference organized by Eureka Science with support of the Higher Colleges of Technology, UAE, it focuses on the interdisciplinary fields of drug discovery, drug therapy and translational medicine.
After the overwhelming success of the first conference held in Dubai in February 2008 (where 11 Nobel laureates attended), the second conference will promise to be a much larger event with over 450 talks delivered and 20 thematic sessions with poster presentations and an associated commercial exhibition.

Throughout the course of the four day conference, you will have the opportunity to both network and hear leaders from the international pharmaceutical, academic and clinical communities.

Benefits of Attending

•    Exchange ideas and network with leading pharmaceutical scientists, clinicians and internists.
•    Brings together top international scientists and clinicians presenting the cutting-edge discoveries, research and new therapeutic drugs.
•    First ever international conference to span the interdisciplinary fields of pre-clinical and clinical drug discovery and drug therapy.
•    First ever international conference to highlight the burgeoning field of Translational Medicine - and the major advances from "bench to bedside" research and practice.
•    Exhibitors can gain direct access to a core audience of professionals and decision makers and have increased visibility through branding and networking at the conference.
•    Obtain a global roundup of Pharmaceutical research capabilities and opportunities.
•    The conference will feature a commercial exhibition and poster sessions.
•    Obtain CME accreditation for select attended clinical lectures.

Who should Attend

The conference will attract a targeted group of senior international decision makers. Delegates and exhibitors will have a valuable, informative and positive experience.
•    CEOs, CROs, senior directors and research associates from the pharmaceutical industry
•    Pharmaceutical scientists
•    Clinicians
•    Internists
•    Medical students


For more information visit: http://www.icddt.com/index.htm